Estamos no ar no ! Saiba mais
ícone de DGX

Quest Diagnostics

235,00 USD
-4,15
1,74%
No fechamento Atualizado 16 de out. 16:00 EDT
Pré-mercado
Após o fechamento do mercado
235,00
0,00
0%
1 dia
-1,74%
5 dias
2,77%
1 mês
-4,89%
3 meses
12,22%
6 meses
22,74%
No acumulado do ano
35,22%
1 ano
25,79%
5 anos
63,51%
10 anos
183%
 

Sobre: Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Funcionários: 57.000

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 53,6%
Neutro 42,9%
Negativo 3,6%
Neutro
Seeking Alpha
há 7 horas
Dividend Champion, Contender, And Challenger Highlights: Week Of October 18
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies that changed their dividends. Companies with upcoming ex-dividend dates.
Dividend Champion, Contender, And Challenger Highlights: Week Of October 18
Neutro
Zacks Investment Research
anteontem
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings
DGX heads into Q3 earnings with expected revenue and EPS growth, fueled by strong clinical demand, advanced diagnostics and operational efficiencies.
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings
Positivo
Zacks Investment Research
há 7 dias
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Neutro
Seeking Alpha
há 14 dias
Dividend Champion, Contender, And Challenger Highlights: Week October 4
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Dividend Champion, Contender, And Challenger Highlights: Week October 4
Neutro
PRNewsWire
há 15 dias
Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence SECAUCUS, N.J., Oct. 1, 2026 /PRNewswire/ -- A new study published in The Journal of Molecular Diagnostics showed that the Haystack MRD® test is highly accurate at detecting residual and recurrent disease, demonstrating clinical performance in specimens from the landmark DYNAMIC colorectal cancer trial series.
Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
Positivo
Zacks Investment Research
há 21 dias
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?
DGX's 36.3% YTD rise reflects momentum in advanced diagnostics, channel growth, AI adoption and cost savings.
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?
Positivo
Zacks Investment Research
há 23 dias
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Positivo
Seeking Alpha
há 23 dias
Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds
Quest Diagnostics Incorporated's recurring testing demand provides a foundation for growth through hospital partnerships, dialysis services, and advanced diagnostics. Their dialysis testing and advanced diagnostics add growth opportunities, although their value ultimately depends on execution and reimbursement. So far, DGX's cash flows seem to be benefiting from the acquisition strategy, but if this falters, it may lead to write-downs of its sizable goodwill on the balance sheet.
Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds
Neutro
PRNewsWire
há 24 dias
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
SECAUCUS, N.J., Sept. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 financial results on Thursday, October 22, 2026, before the market opens.
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
Negativo
The Motley Fool
há 24 dias
Why Quest Diagnostics Holdings Stock Dropped Today
Medicare and Medicaid have been overpaying Quest Diagnostics for years, says the government. Starting next year, they plan to cut reimbursement of lab testing by 15%.
Why Quest Diagnostics Holdings Stock Dropped Today
Gráficos de preços implementados com Lightweight Charts™